CoChat

Emerging MEK inhibitors

McCubrey, James A, Steelman, Linda S, Abrams, Steven L, Chappell, William H, Russo, Suzanne, Ove, Roger, Milella, Michele, Tafuri, Agostino, Lunghi, Paolo, Bonati, Antonio, Stivala, Franca, Nicoletti, Ferdinando, Libra, Massimo, Martelli, Alberto M, Montalto, Giuseppe, Cervello, Melchiorre · 2010 · Expert Opinion on Emerging Drugs
Cited by 63

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

IMPORTANCE OF THE FIELD: The Ras/Raf/MEK/ERK pathway is often activated by genetic alterations in upstream signaling molecules. Integral components of this pathway such as Ras and B-Raf are also activated by mutation. The Ras/Raf/MEK/ERK pathway has profound effects on proliferative, apoptotic and differentiation pathways. This pathway can often be effectively silenced by MEK inhibitors. AREAS COVERED BY THIS REVIEW: This review will discuss targeting of MEK which could lead to novel methods to control abnormal proliferation which arises in cancer and other proliferative diseases. This review will cover the scientific literature from 1980 to present and is a follow on from a review which focused on Emerging Raf Inhibitors published in this same review series. WHAT THE READER WILL GAIN: By reading this review the reader will understand the important roles that genetics play in the response of patients to MEK inhibitors, the potential of combining MEK inhibitors with other types of therapy, the prevention of cellular aging and the development of cancer stem cells. TAKE HOME MESSAGE: Targeting MEK has been shown to be effective in suppressing many important pathways involved in cell growth and the prevention of apoptosis. MEK inhibitors have many potential therapeutic uses in the suppression of cancer, proliferative diseases and aging.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1517/14728210903282760

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 63

Metadata

Authors
McCubrey, J. A., Steelman, L. S., Abrams, S. L., Chappell, W. H., Russo, S., Ove, R., Milella, M., Tafuri, A., Lunghi, P., Bonati, A., Stivala, F., Nicoletti, F., Libra, M., Martelli, A. M., Montalto, G., & Cervello, M.
Venue
Expert Opinion on Emerging Drugs
Published
2010-02-13
Volume
15
Issue
2
Pages
203-223
ISSN
  • 1472-8214 (ISSN-L)
  • 1744-7623
OpenAlex
W2134295475
Cited by
63
References
3
FWCI
3.90
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Emerging MEK inhibitors. https://app.cochat.ai/papers/10.1517/14728210903282760
The paper
McCubrey, J. A., Steelman, L. S., Abrams, S. L., Chappell, W. H., Russo, S., Ove, R., Milella, M., Tafuri, A., Lunghi, P., Bonati, A., Stivala, F., Nicoletti, F., Libra, M., Martelli, A. M., Montalto, G., & Cervello, M. (2010). Emerging MEK inhibitors. Expert Opinion on Emerging Drugs. https://doi.org/10.1517/14728210903282760

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.